There have been issues in the development of PAF-AH inhibitors in the treatment of atherosclerosis, as GlaxoSmithKline’s drug Darapladib failed to pass beyond its second phase III (STABILITY) clinical trial due to a reported lack of prevention in major coronary events and the generation of unexpected side effects including diarrhoea, malodorous faeces, urine, and skin [260]. Here, PLA2G7 is linked to atherosclerosis.